News

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025

• Pre-clinical companies
• OMass Therapeutics

Beacon Therapeutics completes enrolment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

• Pre-clinical companies
• Purespring Therapeutics

OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025

• Pre-clinical companies
• OMass Therapeutics

Northern Gritstone invests in Manchester spinout Apini

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

• Clinical companies
• Quell Therapeutics